H.C. Wainwright analyst Yi Chen raised the firm’s price target on Alimera Sciences to $6 from $5 and keeps a Buy rating on the shares. The company’s sales grew 49% in 2023 with positive adjusted EBITDA and 2024 revenue is expected to exceed $105M, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALIM:
- Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
- Alimera Sciences reports Q4 EPS (7c) vs (54c) last year
- Alimera Sciences (ALIM) Q4 Earnings Cheat Sheet
- Alimera Sciences Launches 2024 Equity Inducement Plan
- The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
